Kiara Russo
Senior Director of Investor Relations
Replay available
uniQure N.V. (NASDAQ: QURE) Q1 2026 earnings conference call, held 2026-05-05. Replay captured from the company's public earnings webcast.

Senior Director of Investor Relations
Chief Executive Officer
Chief Medical Officer
Chief Customer and Strategy Officer
Chief Financial Officer
Thank you for standing by. My name is Liz and I'll be your conference operator today. At this time, I would like to welcome everyone to the Unicure first quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Kiara Russo, Senior Director of Investor Relations. Please go ahead. Good morning, and thank you for joining us for UNICARE's first quarter of 2026 earnings call. Earlier this morning, Unicure released its financial results for the first quarter of 2026, and our press release is available on the Investors and Media section of our website at unicure.com. Our 10Q was also filed with the SEC earlier today. Joining me on the call this morning are Matt Kapisa, Chief Executive Officer, Dr. Waleed Abisab, Chief Medical Officer, Kylie O'Keefe, Chief Customer and Strategy Officer, and Christian Klempt, Chief Financial Officer. After our formal remarks, we'll open the call up for Q&A. Before we begin, please know that we will be making forward-looking statements during this investor call. All statements other than statements of historical fact are forward-looking statements. They are based on management's beliefs and assumptions and on information available to management only as of the date of this conference call. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons. including, without limitation, the factors described in Unicure's most recent SEC filin...